Causaly is a startup that operates in the field of artificial intelligence (AI) and research and development (R&D). The company offers AI solutions that significantly enhance research productivity by reducing the time spent on reading scientific literature. This is achieved through a high-precision, high-accuracy search tool that sifts through the ever-increasing volume of scientific documents, enabling users to discover new insights and make unbiased decisions with confidence.

Causaly's AI has machine-read over 40 million scientific documents, creating a network of more than 350 million directional relationships connecting diseases, pathways, and genes. This vast network allows for a new dimension in scientific exploration and hypothesis generation.

The company's primary clients are pharmaceutical companies, with 12 out of the top 20 pharma companies using Causaly's services to understand disease biology, identify novel targets, and discover biomarkers. The platform is designed to be highly visual and intuitive, requiring no technical expertise to use.

Causaly also assists in the management of the exponential growth of biomedical data, reducing bias and separating signal from noise. This human-centric AI solution can boost research productivity by up to 90%, allowing teams to pursue a more innovative and exploratory direction in drug discovery.

The company makes money by offering its AI solutions to pharmaceutical and biomedical research and development teams. By accelerating the identification and selection of promising biomarkers, Causaly helps to speed up the approval process, saving its clients time and money.

Keywords: Artificial Intelligence, Research and Development, Pharmaceutical Companies, Biomedical Research, High-Precision Search, Disease Biology, Novel Targets, Biomarkers, Drug Discovery, Research Productivity.